
|Videos|May 11, 2017
Indoximod as an Active IDO Pathway Inhibitor in Melanoma
Author(s)Yousef Zakharia, MD
Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses indoximod as an active IDO inhibitor in advanced melanoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































